The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study
Open accessAbstract
Objective: To assess the efficacy and safety of a 24‐week course of abatacept in the treatment of active lupus nephritis and to assess the potential of abatacept to induce “clinical tolerance,” defined as sustained clinical quiescence of lupus nephritis after discontinuation of immunosuppressive therapy. Methods: Patients with active lupus nephritis (n = 134) were enrolled in a randomized, double‐blind phase II add‐on trial in which they received either abatacept or placebo in conjunction with the Euro‐Lupus Nephritis Trial regimen of low‐dose cyclophosphamide (CYC) followed by azathioprine (AZA). The primary efficacy outcome was the frequency of complete response at week 24. Thereafter, patients who met either complete or partial response criteria continued blinded treatment through week 52. During this phase of the study, subjects in the abatacept treatment group in whom a complete response was achieved at week 24 discontinued immunosuppressive therapy other than prednisone (10 mg/day). Results: There were no statistically significant differences between groups with respect to the primary outcome or any of the secondary outcomes, including measures of safety. A complete response was achieved in 33% of the subjects in the treatment group and in 31% of the subjects in the control group at week 24. Fifty percent of the subjects in the treatment group who met complete response criteria and therefore discontinued immunosuppressive therapy at week 24 maintained their complete response status through week 52. Conclusion: The addition of abatacept to a regimen of CYC followed by AZA did not improve the outcome of lupus nephritis at either 24 or 52 weeks. No worrisome safety signals were encountered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
McHorney, C. A., Ware, J. E., Rachel Lu, J. F., & Sherbourne, C. D. (1994) · Medical Care · doi:10.1097/00005650-199401000-00004 · Cited by 4,458
CD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Weening, J. J., D’Agati, V. D., Schwartz, M. M., Seshan, S. V., Alpers, C. E., Appel, G. B., Balow, J. E., Bruijn, J. A., Cook, T., Ferrario, F., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000108969.21691.5d · Cited by 2,008
Hahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050524 · Cited by 1,241
Austin, H. A., Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D., Plotz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,185
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043731 · Cited by 1,128
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101028 · Cited by 1,118
Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., Garrido, E. D. R., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10461 · Cited by 1,077
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F. K., Tang, C. S. O., Wong, R. W. S., Fang, G. X., Ji, Y. L., Lau, C. S., Wong, A. K. M., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 954
Kremer, J. M., Genant, H. K., Moreland, L. W., Russell, A. S., Emery, P., Abud-Mendoza, C., Szechinski, J., Li, T., Ge, Z., Becker, J.-C., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-12-200606200-00003 · Cited by 715
Treatment of Murine Lupus with CTLA4Ig
Finck, B. K., Linsley, P. S., & Wofsy, D. (1994) · Science · doi:10.1126/science.7520604 · Cited by 668
Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
Dooley, M. A., Jayne, D., Ginzler, E. M., Isenberg, D., Olsen, N. J., Wofsy, D., Eitner, F., Appel, G. B., Contreras, G., Lisk, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014460 · Cited by 642
(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068841 · Cited by 567
Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., de Ramon Garrido, E., Danieli, M. G., Abramovicz, D., Blockmans, D., Cauli, A., Direskeneli, H., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.102533 · Cited by 542
Illei, G. G., Austin, H. A., Crane, M., Collins, L., Gourley, M. F., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Steinberg, A. D., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-4-200108210-00009 · Cited by 492
Feldman, C. H., Hiraki, L. T., Liu, J., Fischer, M. A., Solomon, D. H., Alarcón, G. S., Winkelmayer, W. C., & Costenbader, K. H. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37795 · Cited by 487
Incidence of systemic lupus erythematosus race and gender differences
Mccarty, D. J., Manzi, S., Medsger, T. A., Ramsey‐Goldman, R., Laporte, R. E., & Kwoh, C. K. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380914 · Cited by 426
Abatacept in B7-1–Positive Proteinuric Kidney Disease
Yu, C.-C., Fornoni, A., Weins, A., Hakroush, S., Maiguel, D., Sageshima, J., Chen, L., Ciancio, G., Faridi, M. H., Behr, D., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304572 · Cited by 384
Fernández, M., Alarcón, G. S., Calvo‐alén, J., Andrade, R., McGwin, G., Vilá, L. M., Reveille, J. D., & LUMINA Study Group (2007) · Arthritis Care & Research · doi:10.1002/art.22672 · Cited by 272
Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide
Daikh, D. I., & Wofsy, D. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.2913 · Cited by 203
Wofsy, D., Hillson, J., & Diamond, B. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34624 · Cited by 156
Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes
González, L., Toloza, S., McGwin, G., & Alarcón, G. (2013) · Lupus · doi:10.1177/0961203313502571 · Cited by 154
Schiffer, L. E., Sinha, J., Wang, X., Huang, W., von Gonsdorff, G., Schiffer, M., Madaio, M. P., & Davidson, A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.1.489 · Cited by 140
CD28-mediated regulation of multiple myeloma cell proliferation and survival
Bahlis, N. J., King, A. M., Kolonias, D. S., Carlson, L. M., Liu, H. Y., Hussein, M. A., Terebelo, H. R., Byrne, G. E., Levine, B. L., Boise, L., et al. (2007) · Blood · doi:10.1182/blood-2006-03-012542 · Cited by 137
Nair, J. R., Carlson, L. M., Koorella, C., Rozanski, C. H., Byrne, G. E., Bergsagel, P. L., Shaughnessy, J. P., Boise, L., Chanan-Khan, A. A., & Lee, K. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100016 · Cited by 92
The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection
Dai, Z., & Lakkis, F. G. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00008-4 · Cited by 63
What happens after complete withdrawal of therapy in patients with lupus nephritis.
Moroni, G. L., Longhi, S., Giglio, E., et al. (2013) · PubMed · Cited by 62
European genetic ancestry is associated with a decreased risk of lupus nephritis
Richman, I. B., Taylor, K. E., Chung, S. A., Trupin, L. S., Petri, M., Yelin, E. H., Graham, R., Lee, A., Behrens, T. W., Gregersen, P. K., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34567 · Cited by 58
CD28 –B7 Interaction Modulates Short- and Long-Lived Plasma Cell Function
Njau, M. N., Kim, J. H., Chappell, C. P., Ravindran, R., Thomas, L., Pulendran, B., & Jacob, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102728 · Cited by 55
Lupus in Hispanics: A matter of serious concern
Pons‐Estel, G., & Alarcón, G. S. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.12048 · Cited by 19
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
Anders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Almaani, S., Meara, A., & Rovin, B. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05780616 · Cited by 930
Fanouriakis, A., Kostopoulou, M., Cheema, K., Anders, H.-J., Aringer, M., Bajema, I., Boletis, J., Frangou, E., Houssiau, F. A., Hollis, J., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-216924 · Cited by 825
Metadata
- Authors
- The ACCESS Trial Group
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2014-10-26
- Volume
- 66
- Issue
- 11
- Pages
- 3096-3104
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2409438019
- Cited by
- 288
- References
- 33
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.